Ryan & Maniskas, LLP Announces Investigation of Ardea Biosciences, Inc.
April 24 2012 - 10:36AM
Business Wire
Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/rdea) is
investigating potential claims against the board of directors of
Ardea Biosciences, Inc. (“Ardea” or the “Company”) (NASDAQ: RDEA)
concerning possible breaches of fiduciary duty and other violations
of law related to the Company’s efforts to sell Ardea to
AstraZeneca in a transaction valued at approximately $1.26
billion.
Our investigation concerns possible breaches of fiduciary duty
and other violations of law related to the approval of the
transaction by Company’s board of directors; in particular, whether
the Company undertook a fair process to obtain fair consideration
for all shareholders of Ardea. For more information regarding our
investigation, please contact Ryan & Maniskas, LLP (Richard A.
Maniskas, Esquire) toll-free at (877) 316-3218 or by email at
rmaniskas@rmclasslaw.com or visit:
www.rmclasslaw.com/cases/rdea.
Under the terms of the transaction, Ardea shareholders will
receive $32.00 for each Ardea share they own.
If you own shares of Ardea and would like to learn more about
these claims or if you wish to discuss these matters and have any
questions concerning this announcement or your rights, contact
Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign
up online, visit: www.rmclasslaw.com/cases/rdea. You may also email
Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information
about class action cases in general, please visit our website:
www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan & Maniskas, LLP is devoted to protecting the
interests of individual and institutional investors in shareholder
actions in state and federal courts nationwide.
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Oct 2023 to Oct 2024